Skip to content
Open access

Data-driven mapping of known and novel fluid biomarker progression profiles in genetic frontotemporal lobar degeneration

Aug 2026 · Alzheimer's Research & Therapy · 0 citations

TL;DR

The model’s accurate estimation of disease stages underscores the value of DEBM for patient stratification, offer a promising tool to support clinical trial design and provide a temporal ordering of multiple CSF proteins.

Abstract

Recent proteomic studies have identified both established and novel proteins in genetic frontotemporal lobar degeneration (FTLD). However, it remains unclear at what point in the disease these proteins deviate from normal levels and how their trajectories relate to one another. Defining the temporal sequence of protein abnormalities could not only improve disease staging but also help identify biomarkers most sensitive to early disease activity in pathogenic variant carriers. We aimed to apply discriminative event-based modelling (DEBM) to characterize the progression profiles of proteins identified in a previous cross-sectional proteomic analysis. Building on our prior cross-sectional CSF proteomic analysis of genetic FTLD using a proximity extension assay, we selected the top ten significant proteins for each genetic group ( C9orf72 , GRN , MAPT ). We then applied DEBM to characterize temporal dynamics of these proteins separately in each genetic group and evaluated their potential as early disease markers. To validate model performance, each individual was assigned a disease stage according to their position along the estimated disease timeline, based on protein levels and independent of clinical labels. Next, we assessed how well these stages discriminated symptomatic from presymptomatic carriers and non-carriers. Across all genetic groups, NfL consistently became abnormal before TPM3, although the earliest abnormal proteins differed between groups. In C9orf72 , ELAVL4 is the first protein to become abnormal; in GRN SEMA3G and GRN , and in MAPT MMP-10. Estimated individual-level disease stage effectively distinguished symptomatic carriers from presymptomatic carriers and non-carriers, demonstrating high diagnostic accuracy (range AUC 0.74–0.98). Our data-driven findings provide a temporal ordering of multiple CSF proteins, highlighting potential early biomarkers and disease dynamics in different forms of genetic FTLD. In addition, the model’s accurate estimation of disease stages underscores the value of DEBM for patient stratification, offering a promising tool to support clinical trial design.

Read PDF

Similar papers

Open access Sep 2026

Proteo-metabolomic integration identifies stage-specific candidate biomarkers for Parkinson’s disease

An integrated multi-omics approach provides a robust framework for stage-specific PD monitoring and potential clinical deployment using multi-omics machine learning to identify biofluid-specific signatures and evaluated predictive performance.

A. Galal, Ahmed Moustafa, Mohamed Salama · 0 citations
Open access Sep 2026

From genes to pathways: genetic convergence in early-onset Parkinsons disease in India

The first pathway resolved South Asian genetic profile and a framework for comparative studies across populations are provided, with different contributions from P/LP-associated and VUS associated gene sets.

R. Menon, A. I. Khan, D. Elangovan et al. · 0 citations
Review Open access Sep 2026

Presymptomatic Amyotrophic Lateral Sclerosis: From Early Biomarker Detection to Phenoconversion Prediction

The ATLAS study, a trial of tofersen initiated in clinically presymptomatic carriers of superoxide dismutase 1 (SOD1) variants, incorporated specific SOD1 variants and within-person NfL increases into risk monitoring and used these criteria to select participants for the randomized treatment phase.

Min Chen, He-Xian Li, Qing-Wen Jin · 0 citations
Open access Sep 2026

Molecular subgroups of ALS patients with distinct survival outcomes identified through plasma proteomics

Cell-type enrichment analysis indicating a broad cellular origin of the circulating proteome, with contributions from nervous system cells, vascular cells, immune cells, and muscle cells, highlights the potential of plasma proteomics for clinically meaningful patient stratification in ALS.

I. Aksoylu, L. Azizi, L. Öijerstedt et al. · 0 citations
Open access Sep 2026

Proteomic profiling of baseline CSF and serum from HDClarity identifies signatures for Huntington disease staging and stratification

Background Sensitive biomarkers that objectively stage Huntington disease (HD) are needed to improve participant stratification and facilitate the enrichment of clinical trials with biologically and clinically homogeneous populations. The HDClarity study, an international longitudinal biofluid collection initiative for...

N. Caron, Inês Caldeira Brás, J. Barron et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.